185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial
H. S. Rugo, Shanu Modi(Memorial Sloan Kettering Cancer Center), David Cameron(Corewell Health), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Eriko Tokunaga(National Hospital Organization Kyushu Cancer Center), Fátima Cardoso(Breast Cancer Alliance), Joohyuk Sohn(Yonsei University), Ursula Hasler-Strub(Kantonsspital Graubünden), Cecilia Orbegoso, F-C. Cheng(Daiichi Sankyo (United States)), K. Mezei, Rajaganesh Rajagopalan(Daiichi Sankyo (United States)), Henrik Lindman(Uppsala University), Naoto T. Ueno(Breast Cancer Care), Adeep Puri(Daiichi Sankyo (United States)), Aleix Prat(Hospital Clínic de Barcelona), William Jacot(Inserm), Halle C. F. Moore(Cleveland Clinic)
Cited by 11
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Current and future burden of breast cancer: Global statistics for 2020 and 2040
|The Breast|2022|3.3k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k